Anti-aging formulation of rosmarinic acid-loaded ethosomes and liposomes / Çiğdem Yücel, Gökçe Şeker Karatoprak, İsmail Tuncer Değim
Abstract The study was aimed to evaluate the effectiveness of rosmarinic acid (RA) loaded ethosomes (ETHs) and liposomes (LPs) when subjected to the transdermal application. RA-loaded ETHs and LPs were prepared, optimised, and characterised. The ex vivo permeation studies of formulations using mouse abdominal skin were performed. Antioxidant activities and the inhibitory effects of formulations on collagenase and elastase enzymes were measured. Optimised ethosomal formulation (F3) was showed nanometric size range (138 ± 1.11 nm) and greatest entrapment (55 ± 1.80%), was selected for further transdermal permeation studies. Skin permeation profile of the nanoformulations analysed by HPLC revealed an enhanced permeation of ETHs. Transdermal flux of ETHs was found to be higher than RA solution and LPs. Enzyme inhibitions of ETHs were the significant difference found between ETHs and LPs ( p < 0.05). ETHs were found to be more effective and successful than LPs. Results suggest that ETHs are more effective than LPs for transdermal delivery of RA.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2019 |
---|---|
Erschienen: |
2019 |
Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
---|---|
Enthalten in: |
Journal of microencapsulation - 36(2019), 2, Seite 180-191 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Yücel, Çiğdem [VerfasserIn] |
---|
Links: |
FID Access [lizenzpflichtig] |
---|
Themen: |
Anticollagenase |
---|
Umfang: |
1 Online-Ressource (12 p) |
---|
doi: |
10.1080/02652048.2019.1617363 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
KFL011203374 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | KFL011203374 | ||
003 | DE-627 | ||
005 | 20231109210045.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230714s2019 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1080/02652048.2019.1617363 |2 doi | |
035 | |a (DE-627)KFL011203374 | ||
035 | |a (KFL)prod_LgpH_10.1080/02652048.2019.1617363 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
084 | |a PHARM |q DE-84 |2 fid | ||
100 | 1 | |a Yücel, Çiğdem |e verfasserin |4 aut | |
245 | 1 | 0 | |a Anti-aging formulation of rosmarinic acid-loaded ethosomes and liposomes |c Çiğdem Yücel, Gökçe Şeker Karatoprak, İsmail Tuncer Değim |
264 | 1 | |c 2019 | |
300 | |a 1 Online-Ressource (12 p) | ||
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract The study was aimed to evaluate the effectiveness of rosmarinic acid (RA) loaded ethosomes (ETHs) and liposomes (LPs) when subjected to the transdermal application. RA-loaded ETHs and LPs were prepared, optimised, and characterised. The ex vivo permeation studies of formulations using mouse abdominal skin were performed. Antioxidant activities and the inhibitory effects of formulations on collagenase and elastase enzymes were measured. Optimised ethosomal formulation (F3) was showed nanometric size range (138 ± 1.11 nm) and greatest entrapment (55 ± 1.80%), was selected for further transdermal permeation studies. Skin permeation profile of the nanoformulations analysed by HPLC revealed an enhanced permeation of ETHs. Transdermal flux of ETHs was found to be higher than RA solution and LPs. Enzyme inhibitions of ETHs were the significant difference found between ETHs and LPs ( p < 0.05). ETHs were found to be more effective and successful than LPs. Results suggest that ETHs are more effective than LPs for transdermal delivery of RA | ||
653 | |a Rosmarinic acid | ||
653 | |a ethosome | ||
653 | |a liposome | ||
653 | |a skin penetration | ||
653 | |a antioxidant activity | ||
653 | |a anticollagenase | ||
653 | |a antielastase activity | ||
700 | 1 | |a Şeker Karatoprak, Gökçe |e verfasserin |4 aut | |
700 | 1 | |a Değim, İsmail Tuncer |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of microencapsulation |d Abingdon : Taylor & Francis Group, 1984 |g 36(2019), 2, Seite 180-191 |h Online-Ressource |w (DE-627)KFL000005967 |w (DE-600)1491079-2 |w (DE-576)079719244 |x 1464-5246 |7 nnns |
773 | 1 | 8 | |g volume:36 |g year:2019 |g number:2 |g pages:180-191 |
856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/02652048.2019.1617363 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
912 | |a ZDB-1-TFE | ||
912 | |a GBV_KFL | ||
912 | |a FID-PHARM | ||
935 | |i IMPORT_0628_prod_LgpH_02 | ||
951 | |a AR | ||
952 | |d 36 |j 2019 |e 2 |h 180-191 |